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Abstract
OBJECTIVE: To systematically evaluate the effec-
tiveness and safety of heat-sensitive moxibustion
(HSM) on asthma.
METHODS: Large databases in China and overseas
were searched by electronic and manual means to
collect information on randomized controlled trials
(RCTs). Two evaluators independently extracted da-
ta and evaluated the quality of RCTs according to
Cochrane Review Handbook v5.0. RevMan v5.0.20
was used for statistical analyses.
RESULTS: Fourteen RCTs involving 637 patients
were collected. Thirteen RCTs compared the effects
of HSM and Western Medicine. After 3-month treat-
ment and after 6-month follow-up, there was no
significant difference in effective rate [relative risk
(RR)=1.01, 95% CI (0.92, 1.12), and 1.12, (0.93, 1.36),
respectively], in the asthma control test score of
asthma symptoms [weighted mean difference
(WMD)=﹣ 1.54, 95% CI (﹣ 3.54, 0.47), and 1.41,
(﹣ 0.48, 3.29), respectively] and in the forced expi-
ratory volume in 1 second (FEV1) and peak expirato-
ry flow (PEF). One RCT compared the effect of HSM
with warm-suspended moxibustion. After 6-month
follow-up, there was a significant difference in FEV1
and PEF [WMD=0.51, 95% CI (0.10, 0.92), and 1.78,
(1.06, 2.50), respectively]. After 3-month treatment,
there was no significant difference between the
two groups. One RCT compared the effect of HSM
with acupoint application. After 3-month treat-
ment, there was no significant difference in the ef-
fective rate [RR=0.68, 95% CI (0.42, 1.12)].
CONCLUSION: HSM did not show superiority to
conventional Western Medicine and acupoint appli-
cation in terms of curative effects, and may be su-
perior to warm-suspended moxibustion with re-
gard to long-term curative effects. Because of low
quality of the included RCTs, this conclusion must
be bolstered with higher-quality RCTs.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
The incidence of asthma (a chronic inflammatory dis-
ease in the airway involving many types of cells) is in-
creasing worldwide. According to the global initiative
for asthma (GINA) issued in 2008, about 300 million
people have asthma and 180 000 people die due to
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asthma each year.1,2 The incidence of asthma in West-
ern European countries has doubled in the past de-
cade. It has been estimated that by 2025 the number
of individuals with asthma will increase by 100-150
million worldwide.3 Therefore, improving the preven-
tion and treatment of asthma and controlling its symp-
toms has become a public-health issue worldwide.
The pathogenesis of asthma is very complex.4 Asthma
is treated mainly with beta-2 adrenoceptor agonists
and glucocorticoid hormones, but long-term use of
such medications can cause side effects.5 Therefore, the
search for a therapy with better, stable and sustainable
curative effects and with minor toxic side-effects has be-
come a key issue in the prevention and treatment of
asthma.
Acupuncture-moxibustion has been used for a consider-
able time in China to treat asthma. Its unique curative
effect and safety have been affirmed by researchers. Sev-
eral studies have suggested that the mechanism of acu-
puncture-moxibustion against asthma is mainly
through: improvement of ventilation; control of in-
flammatory reactions; regulation of immune functions;
and adjustment of the nerve-endocrine network.4-6
Moxibustion has been shown to reduce levels of immu-
noglobulin-E and the soluble interleukin-2 receptor in
serum and enhance the contents of T3, T4, T8, T4/
T8 and natural-killer cells.7
Therefore, the anti-asthma effects of moxibustion ther-
apies [e.g., heat-sensitive moxibustion (HSM),
crude-herb moxibustion, suppurative moxibustion,
warm-suspended moxibustion] have become the foci
of research. In recent years, HSM has shown consider-
able clinical effectiveness.8 Systematic evaluation of the
clinical trials that have employed HSM to treat asthma
is lacking, a gap in knowledge that we have addressed
in the present study.
MATERIALS ANDMETHODS
Inclusion criteria for articles
We included articles that were reports of randomized
controlled trials (RCTs) irrespective of whether they
were blinded or not. Articles could be written in Chi-
nese or English. The targets of research were male or fe-
male patients aged >15 years and the source of these pa-
tients. Explicit diagnostic standards were based on the
Guide for Preventing and Treating Bronchial Asthma
issued by the Asthma group (respiratory disease
branch) of the China Medical Association1 and GINA.9
HSM had to have been used in the trial group, and
Western Medicines or Chinese drugs used in the con-
trol group. The outcome indices were the: Asthma
Control Test (ACT); frequency of asthma attacks; St
George's Respiratory Questionnaire (SGRQ); Tradi-
tional Chinese Medicine (TCM) score of asthma symp-
toms; pulmonary function [forced expiratory volume
in one second (FEV1), peak expiratory flow (PEF),
FEV1/forced vital capacity (FVC), maximal mid-expira-
tory flow (MMEF)]; effective rate(defined as more
than 30% reduction of asthma attack frequenc by year
according to the guiding principle of new drug of
TCM); controlled rate (defined as the rate of "con-
trolled"and "partly controlled " in GINA, described in
Table 1); and adverse reactions.
Exclusion criteria for articles
We did not include articles that: were repeatedly re-
trieved or reissued; based on treatment with HSM and
other therapies; included patients with other serious
chronic diseases (e.g., diabetes, chronic obstructive dis-
eases of the lung).
Retrieval policy for articles
Articles were retrieved by electronic searches from data-
bases in China [Chinese Biomedical Literature Data-
base (1979-2013), China National Knowledge Infra-
structure Database (1979-2013), Chinese Science and
Technology Periodical Database 1989-2013), Wan-
fang Database (1998-2013) and overseas [PubMed
(1966-2013), Embase (1980-2013), the Cochrane Li-
brary (issue 1 in 2013)]. The database at the Library of
Jiangxi Traditional Chinese Medicine College was
searched for the full texts not obtained by electronic re-
trieval. The search terms in Chinese were "heat-sensi-
tive moxibustion" and "asthma", whereas those in Eng-
lish were "heat-moxibustion" and "asthma". All search-
es were carried out until 30 April 2013.
Method of evaluation
Data extraction: two evaluators read the titles and ab-
stracts of articles independently. They excluded RCTs
that obviously did not conform to the inclusion crite-
ria and read the full-text of RCTs that might. Each
Characteristic
Daytime symptoms
Limitations of activities
Nocturnal symptoms/awakening
Need for reliever /rescue treatment
Lung function (PEF or FEV1)
Controlled
None (twice or less/week)
None
None
None (twice or less/week)
None
Partly controlled
More than twices/week
Any
Any
More than twices/week
<80% predicted or personal best (if known)
Uncontrolled
Three or more fea-
tures of partly con-
trolled asthma pres-
ent in any week
Table 1 Levels of asthma control in GINA
Notes: GINA: global initiative for asthma; FEV1: forced expiratory volume in one second; PEF: peak expiratory flow.
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evaluator checked the choices of the other evaluator.
Disagreements were settled by consensus. If consensus
could not be reached, a third evaluator made the final
decision.
Evaluation of quality: according to the Cochrane Hand-
book for Systematic Reviews of Interventions (v5.1.0),10
measures for evaluating the risk of bias comprise six
items:10 (a) method of randomized distribution; (b)
concealment of the distribution plan; (c) blinding
method for the targets of research, practitioners of the
therapeutic plan, and those measuring outcomes; (d)
wholeness of consequent data; (e) result of research in-
to selective reports; and (f) other sources of deviation.
Each evaluator checked the choices of the other evalua-
tor. Disagreements were settled by consensus. If con-
sensus could not be reached, a third evaluator made
the final decision.
Statistical analyses
RevMan v5.0.20 10 provided by Cochrane Coordina-
tion Net was used to carry out Meta-analysis. A hetero-
geneous test was conducted among studies. With P<0.1
as the test standard, if statistic heterogeneity among
studies was absent, a fixed-effect model was used; if sta-
tistic heterogeneity among studies was present, the
source of heterogeneity was found. If there was no clin-
ical or methodological heterogeneity, a randomized-ef-
fect model was used to carry out combined analyses.
The weighted mean difference (WMD) or standardized
mean difference was used for continuous variables. Rel-
ative risk (RR) was used for categorical variables. Both
effects were expressed with a 95% confidence interval
(CI). P≤0.05 was considered significant. Descriptive
analyses were carried out only for obvious clinical het-
erogeneity among studies. Sensitivity analyses were
used to test the stability of the results if necessary.
RESULTS
Search results
Among the preliminarily selected articles in Chinese,
three were theses issued at conferences, 31 theses were
for doctorates, and 64 theses were published in periodi-
cals. Finally, through screening, 14 articles involving
637 cases were selected (Figure 1).
Characteristics of research
Type of research: all the included studies were sin-
gle-center RCTs and were shown in Table 2.
Targets of research: the study cohorts comprised outpa-
tients or inpatients. All the included studies adopted
the diagnostic standard set in the Guide for Preventing
and Treating Bronchial Asthma. All but two studies de-
tailed the inclusion and exclusion criteria.11,13 Eight
studies detailed the criteria for rejection and suspen-
sion.12,14,15-17,22-24
Intervention measures: comparisons were made among
three groups in one study,11 among four groups in an-
other study12 and between two groups in the remainder
of the studies. HSM was used in the trial group in all
studies. Seretide was used in the control group of 12
RCTs.11,13-15,17-24 Changdi was used in the control group
of one trial.16 Suspended moxibustion was used in the
Preliminarily selected articles (n=98)
After headlines and abstracts had been
read, excluded were•Repeatedly retrieved articles (n=46)•Summary, commentary and
exploration (n=11)•Abstract of conferences (n=3)
Articles to be further screened (n=38)
After full texts had been read,
excluded were•Observations on cases (n=6)•Non-randomized control trials (n=6)
Possibly included articles (n=26)
After full texts had been read,
excluded were•Repeatedly issued articles (n=3)•Other therapies (n=9)
Definitely included articles (n=14)
Figure 1 Article-retrieving procedure
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control group of one trial.11 Acupoint application was
used in the control group of 1 trial.12
Measurement indices: indices of pulmonary function
were used in 13 studies.11,13-24 The ACT score was used
in 10 trials.13-24 The effective rate was used in eight stud-
ies12-14,17-21 The controlled rate was used in 11 trials.13-22,24
The SGRQ was used in one study.15 The TCM score
of asthma symptoms was used in three trials.15,22,24 Ad-
verse reactions were reported in two studies.18,24
Quality of included RCTs
Most of the included RCTs were of high quality. Only
two trials did not employ a standardized method of
randomization.11,12 One trial used a digital method for
randomization,15 and the remainder adopted a central
method of randomization. None of the trials used a dis-
tribution-concealing method. Four studies used a sin-
gle blinding method for evaluators.15,18,19,22 Twelve trials
provided detailed baseline data,11-22 and the remainder
only mentioned baseline conditions and comparability.
Two trials reported the conditions under which fol-
low-up visits were carried out20,22 The risk of bias in the
included RCTs is shown in Figure 2.
HSM vs Western Medicine
Effective rate of controlling asthma: of the RCTs that
compared HSM and Western Medicine, nine used the
Notes: Liang Chao 2010 had three groups and Zhang Yuanbing 2012 had four groups. According to the aim of this research, only two
groups were used. The trial group were given heat-sensitive mosibustion in all included studies; The treatment course was 3 months in all
trials. ACT: asthma control test; SGRQ: St George's respiratory questionnaire; FEV1: forced expiratory volume in one second; PEF: peak
expiratory flow; FVC: forced vital capacity; MMEF: maximal mid-expiratory flow; TCM: Tradtional Chinese Medicine; RCT: random-
ized controlled trial.
Included trial
Liang C et al
201011
Zhang YB et al
201212
Song NC et al
201213
Liang C et al
201014
OY BS et al
201115
Nie H 201116
Yang K 201017
Ma HJ 201118
Liao Y 201019
Zuo TP 201020
Lu YX 201021
Wu YJ 201022
Dou YX 201023
Si JZ 201124
Cohort
Trial group
15
30
32
17
28
30
21
12
12
12
21
30
21
36
Control group
15
30
32
19
29
30
21
12
12
12
21
30
21
36
Control group
Seretide/warm-suspended moxi-
bustion
Acupoint application
Seretide
Seretide
Seretide
Changdi
Seretide
Seretide
Seretide
Seretide
Seretide
Seretide
Seretide
Seretide
Outcome indices
Pulmonary functions: FEV1, PEF
Effective rate, ECP concentration
ACT score, effective rate, controlled rate
ACT score, Pulmonary functions: FEV1 and
PEF, effective rate, controlled rate
SGRQ score, ACT score, TCM score of
symptoms, Pulmonary functions: FEV1, PEF,
FEV1/FVC and MMEF, controlled rate
Controlled rate
ACT score, controlled rate, effective rate,
Pulmonary functions: FEV1 and PEF
ACT score, controlled rate, effective rate,
Pulmonary functions: FEV1 and PEF
ACT score, controlled rate, effective rate,
Pulmonary functions: FEV1 and PEF
ACT score, controlled rate, effective rate,
Pulmonary functions: FEV1 and PEF
ACT score, controlled rate, effective rate
ACT score, TCM score of symptoms,
Pulmonary functions: FEV1, PEF, FEV1/FVC
and MMEF, controlled rate
Pulmonary functions: FEV1 and PEF
ACT score, TCM score of symptoms,
Pulmonary functions: FEV1 and PEF
Table 2 General features of included RCTs
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effective rate transformed from the ACT score13-18,20,22,24
(Figure 3). Meta-analysis showed no significant differ-
ence between the two groups after 3-month treatment
[RR=1.01; 95% CI (0.92, 1.12)] and after 6-month fol-
low-up [RR=1.12; 95% CI (0.93, 1.36)].
ACT score of asthma symptoms
In the eight trials that used the ACT score of asthma
symptoms,13,15,17,18-21,24 Meta-analysis showed no signifi-
cant difference between the two groups after 3-month
treatment [WMD=﹣ 1.54; 95% CI (﹣ 3.54, 0.47)]
and after 6-month follow-up [WMD=1.41; 95% CI
(﹣0.48, 3.29)] (Figure 4).
Pulmonary function: FEV1
In the eight trials that measured FEV114-18,22-24, Me-
ta-analysis showed no significant between the two
groups after 3-month treatment [WMD=﹣0.37; 95%
CI ( ﹣ 2.27, 1.54)] and after 6-month follow-up
[WMD=2.33; 95% CI (﹣0.48, 5.14)] (Figure 5).
Pulmonary function: PEF
In the six trials that measured PEF,15-18,23-24 Meta-analy-
sis showed no significant difference between the two
groups after 3-month treatment [WMD=﹣0.17; 95%
CI ( ﹣ 2.69, 2.34)] and after 6-month follow-up
[WMD=﹣3.09; 95% CI (﹣14.01, 7.83)] (Figure 6).
Figure 3 Meta-analysis of the effective rate of heat-sensitive moxibustion compared withWestern Medicine
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
Figure 2 Analysis of bias in the included studies
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Pulmonary function: other indices
In the two trials that used other indices of pulmonary
function,15,22 Meta-analysis showed that after 3-month
treatment, there was no significant difference between
the two groups with regard to MMEF [WMD=﹣1.30;
95% CI (﹣ 3.52, 0.92)] and FEV1/FVC [WMD=﹣
1.71; 95% CI (﹣3.33, 0.99)]. In these two trials,15,22 af-
ter 3-month treatment, there was no significant differ-
ence between the two groups in the TCM score of asth-
ma symptoms [WMD=﹣0.37; 95%CI (﹣1.33, 0.59)].
HSM vs warm-suspended moxibustion
In the one study that focused on HSM vs warm-sus-
pended moxibustion, there was no significant in FEV1
between the two groups 11,17 after 3-month treatment
[WMD=0.09; 95% CI (﹣0.31, 0.49)] but a significant
difference was observed after 6-month follow-up
[WMD=0.51; 0.10-0.92). There was no significant dif-
ference in PEF between the two groups11,17 after
3-month treatment [WMD=0.35; 95% CI (﹣ 0.36,
1.06)] but a significant difference was noted after
Figure 5 Meta-analysis of FEV1 of heat-sensitive moxibustion compared withWestern Medicine
FEV1: forced expiratory volume in 1 second.
Figure 4 Meta-analysis of the ACT score of heat-sensitive moxibustion compared withWestern Medicine
ACT: asthma control test.
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6-month follow-up [WMD=1.78; 95%CI (1.06, 2.50)].
HSM vs acupoint application
In the one study that focused on HSM vs acupoint ap-
plication,12 after 3-month treatment, there was no sig-
nificant difference in the effective rate between HSM
and acupoint application (RR=0.68; 95% CI (0.42,
1.12)].
Adverse reactions
Adverse reactions were reported in 2 studies. Ma18 re-
ported that after 5-day treatment, one patient in the
HSM group had asthma onset before leaving the trial
and one patient in the Western Medicine group had
medication-related chest tightness. Si24 reported that af-
ter 2-day treatment, one patient in the HSM group
had the onset of mild acute infection in the upper re-
spiratory tract and, after treatment, he remained in the
study. After 1-month treatment with Seretide, one pa-
tient in the Western Medicine group had a hoarse
voice that was sometimes accompanied by a sore throat
and white phlegm; after spraying the drug in the throat
before rinsing the mouth, the symptoms improved and
he remained in the study. Hence, Seretide could cause
adverse reactions in the throat.
DISCUSSION
We systematically evaluated 14 RCTs involving 637
patients. Most trials were carried out with small co-
horts and had low methodological quality. All but two
RCTs used central or digital methods of randomiza-
tion. No trial described a distribution-concealing meth-
od. Four trials adopted a blinding method for evalua-
tors. Most trials provided detailed baseline data. Over-
all, the low quality of included trials would lead to clin-
ical heterogeneity and bias, so evaluations should be
treated with caution.
RCTs are used to investigate the effects of interven-
tions. Randomization is one of the three important fea-
tures (along with the method of blinding, and having
controls) in designing a RCT. In a RCT, randomiza-
tion should comprise at least four aspects: type of ran-
domization method; order of randomized distribution;
distribution-concealing method; and specific practitio-
ners.
The included RCTs described the randomization meth-
od, but a specific description of the randomization pro-
cess (especially distribution-concealing measures and
information on practitioners) was lacking. Estimating
the minimum number of samples in a RCT is crucial.
Too few samples will result in a lack of statistical pow-
er, whereas too many samples will consume manpow-
er, resources and time. All the included RCTs had
small cohorts and did not provide detailed information
about the patients. The method of blinding has been
the focus of discussion on RCTs of acupuncture-moxi-
bustion. Acupuncture-moxibustion involves very skil-
ful manipulation, and blinding subjects and practitio-
ners (particularly between acupuncture-moxibustion
and drugs) is very difficult. However, the method of
blinding can be practiced on those in charge of evaluat-
ing outcome indices and data (i.e., they do not know
which groups the patients are in). The included RCTs
mostly used the blinding method on statisticians and
study subjects, and the blinding method on the latter
was different types of moxibustion. The baseline data
in some of the RCTs were described in simple terms
without giving specific statistical values.
The present study showed that designers and practitio-
ners of RCTs need to have much better basic knowl-
edge on RCTs. Smaller pilot trials should be carried
out and sample contents calculated before implementa-
tion of the larger RCT. RCTs of acupuncture-moxibus-
Figure 6 Meta-analysis of PEF of heat-sensitive moxibustion compared withWestern Medicine
PEF: peak expiratory flow.
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tion should be reported according to the international-
ly accepted CONSORT and STRICTA25,26 criteria to
enhance the quality of clinical research into the use of
acupuncture-moxibustion against asthma.
We wished to evaluate the clinical effectiveness of
HSM on asthma. HSM compared with the conven-
tional Western Medicine Seretide was used in 12
RCTs and Meta-analysis showed no significant differ-
ences in the effective rate, parameters of pulmonary
function, and ACT score between the two groups. In
Western Medicine, glucocorticoid hormones are used
to dampen inflammation and beta-2 adrenoceptor ago-
nists to relax bronchial smooth muscle to alleviate
spasms, thereby resolving the symptoms of asthma.
The included RCTs showed no significant differences
in curative effects between HSM and Seretide, but
could better-designed RCTs be developed to ascertain
differences in curative effects between these two thera-
pies? If it can be confirmed that HSM is not inferior to
Seretide in terms of curative effects, HSM could re-
place Seretide in the treatment of chronic asthma.
With regard to safety, inhaling Seretide will probable
cause adverse reactions in the mouth and throat.
Hence, infants, elderly subjects and those with poor
pulmonary function will encounter difficulties in inhal-
ing Seretide into the lower respiratory tract, resulting
in suboptimal effects. The included RCTs showed that
HSM had fewer adverse reactions and better safety
than Seretide. In one RCT, there was a significant dif-
ference in FEV1 and PEF between HSM and suspend-
ed moxibustion after 6-month follow-up and no signifi-
cant difference after 3-month treatment. HSM did not
show superiority to acupoint application in terms of cu-
rative effects.
HSM did not show superiority to conventional West-
ern Medicine and acupoint application in terms of cu-
rative effects, and may be superior to warm-suspended
moxibustion with regard to long-term curative effects.
Because of low quality of the included RCTs, this con-
clusion must be bolstered with higher-quality RCTs.
We suggest that in future studies, a strict and practica-
ble multi-center RCT with a large patient cohort
should be designed to assess the effectiveness of HSM
on asthma.
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